Table 5.
Comparison of TI-RADS scores: Histopathological findings in the study group for each category and calculated malignancy risk for each model.
| Total | Benign | Malignant | Calculated Risk | |
|---|---|---|---|---|
| EU TI-RADS | ||||
| 2 | 6 | 6 | 0 | 0% |
| 3 | 18 | 17 | 1 | 5.55% |
| 4 | 68 | 56 | 12 | 17.6% |
| 5 | 41 | 19 | 22 | 53% |
| ACR TI-RADS | ||||
| 1 | 5 | 5 | 0 | 0% |
| 2 | 25 | 23 | 2 | 8% |
| 3 | 0 | 0 | 0 | - |
| 4 | 64 | 48 | 16 | 25% |
| 5 | 39 | 22 | 17 | 43.58% |
| Horvath TI-RADS | ||||
| 2 | 19 | 18 | 1 | 5.26% |
| 3 | 5 | 5 | 0 | 0% |
| 4A | 44 | 38 | 6 | 13.63% |
| 4B | 36 | 24 | 12 | 33.33% |
| 5 | 29 | 13 | 16 | 55.17% |
| French TI-RADS | ||||
| 2 | 6 | 6 | 0 | 0% |
| 3 | 19 | 19 | 0 | 0% |
| 4A | 59 | 56 | 3 | 5.08% |
| 4B | 27 | 13 | 14 | 51.85% |
| 5 | 22 | 4 | 18 | 81.8% |
| French TI-RADS + 4D CD | ||||
| 2 | 6 | 6 | 0 | 0% |
| 3 | 19 | 19 | 0 | 0% |
| 4A | 51 | 49 | 2 | 3.92% |
| 4B | 32 | 20 | 12 | 37.5% |
| 5 | 25 | 4 | 21 | 84% |